Concerns regarding the attenuations of vaccine effectiveness (VE) consequent to repeated vaccination were raised in 1970s, although the results were inconclusive [1, 2] . This topic has elicited significant interest from many investigators after recent studies have reported the effects of repeated vaccinations [3] [4] [5] [6] [7] . One recent meta-analysis found no statistically significant effect of vaccination in the previous season, whereas another meta-analysis reported that attenuating effects were more obvious against H3N2 than against H1N1 pdm or influenza B [8, 9] . The meta-analyses raised an important issue, specifically, that most studies accounted only for vaccine history in the previous 1 season but a few included vaccination histories over multiple seasons. Moreover, Belongia et al raised an unresolved question regarding the incidence of negative effects: namely, whether first-vaccinated individuals might have contracted a natural infection during the prior season, with resulting potent, natural immunities [8] . Although previous serologic studies have identified a significant negative association between the number of prior vaccinations and the serologic response, no study has clinically evaluated the dose-response relationship [10, 11] . To address these unsolved questions, an analysis of repeated vaccinations should include the histories of prior multiple vaccinations and natural infection over multiple seasons [12] .
Furthermore, school-aged children are the most important vectors for community transmission, and a certain proportion of them have histories of natural infections [13, 14] . Some national recommendations and school-located influenza vaccination programs have led to an increase in the proportion of children who have been immunized over multiple seasons [15, 16] .
Therefore, we conducted a study to elucidate the association between the negative effects and dose-dependency of prior serial vaccinations among schoolchildren on a Japanese island for whom recorded vaccination status and previous medically attended influenza histories (MA-flu) over multiple seasons were available.
METHODS

Study Design
The current study was conducted at a single hospital (Kamigoto Hospital [KH] ) located on a small island in Japan. Details of the study design were described previously [12] . This island has limited health facilities and KH is the only facility with inpatient care and a pediatric department. KH is located in the most populated area and near several schools. School-aged children repeatedly attend KH with influenza-like illness (ILI) symptoms, and most influenza diagnoses in this population were made at this hospital (Supplementary Table 1 ). The influenza vaccine coverage on this island is relatively high, particularly among school-aged children (Supplementary Table 1 ).
In Japan, the trivalent split-virion influenza vaccine (TIV) via subcutaneous injection has been used as the standard method in Japan [17] . Generally, the TIV has a cost per dose of approximately 3600 yen (~30 US dollars [USD]); however, local government subsidies on the island have led to a cost per dose of 1000 yen (~10 USD). Supplementary Tables 1-3 list the vaccine compositions used in Japan during each season, the national endemic influenza type, and vaccine coverage and influenza incidence on this island.
Data Collection
This study obtained information about current and past vaccination status from the vaccine registry system in local government. All influenza vaccinations on the island were registered in this system. KH has an ILI registry system that electronically records the relevant medical information and rapid diagnostic test (RDT) results of all patients with ILI symptoms. Influenza RDTs (Espline Influenza A and BR, Fujirebio Inc, Japan) were routinely performed for all patients with ILI symptoms. Findings of our previous study showed that the sensitivity and specificity of the RDT for detecting influenza A and/or B were 78.6% (95% confidence interval [CI], 73.9%-83%) and 95.3% (95% CI, 93%-97.7%), respectively [18] . This ILI registry allowed us to collect precise data of the previous RDT-confirmed influenza episodes. We restricted data collection to episodes of schoolchildren aged 9 years (third-or fourth-grade elementary) to 18 years (third-grade high school) because this population has limited mobility and information from the 3 previous seasons could feasibly be collected from the ILI and vaccine registries.
Data Analysis
The method used to handle multiple episodes was previously described and is shown in Supplementary Table 4 [12] . RDTpositive episodes of different genus types of influenza were excluded from the analysis of each type. For instance, influenza A-positive cases were excluded from calculations of VE against influenza B. Vaccine status was defined as "vaccinated" at 14 days after vaccine administration. This study used a test-negative, case-control study design to estimate odds ratio (ORs). The characteristics of the ILI patients were compared by outcome categories (test-negative vs test-positive). VE against influenza was calculated as 1 minus the OR. We used 3-step analyses to evaluate VE. First, we calculated VE according to the vaccine status during only the current season. Second, we assessed the effects of vaccination during 1 prior season, thus yielding 4 groups: neither season, prior season only, current season only, and both seasons. Among subjects who were vaccinated in the current season, VEs between the "current season only" group and the "both seasons" group were compared using χ 2 tests. Next, we estimated VE according to the vaccine status during the current season and 3 previous seasons. Subjects unvaccinated during the current and 3 previous seasons served as the reference group. To assess the effects among subjects with prior episodes of MA-flu, the fraction of prevented MA-flu in the current season (ie, prevented fraction [PF]) among individuals who were exposed to MA-flu during the previous season was also calculated as 1 minus the OR [19] . Multilevel mixed-effects logistic regression models were used to calculate the unadjusted and adjusted ORs for VE and PF. Because the individuals and school class were nested, a model with 3 levels (ILI episode, individual, and school class) was applied to assess the VE. All potential confounders, including age, sex, the presence of chronic conditions, duration of symptoms, season/year of visit, phase of the season, and history of RDT-confirmed MA-flu in the 3 prior influenza seasons, were included in the models. Each influenza season was divided into 3 phases (ie, early, middle, and late phases). The presence of pulmonary diseases, cardiovascular diseases, and others were treated as chronic conditions. To assess dose-dependent association between VE in the current season and prior vaccine doses, we conducted a dose-response analysis using generalized least-squares regression [20] . The data were managed using Microsoft Access software (Redmond, Washington), and statistical analyses were performed using Stata software (version 13; StataCorp, College Station, Texas). P values <.05 were considered significant. This study was approved by the institutional review boards of KH and the Institute of Tropical Medicine at Nagasaki University, Japan.
RESULTS
During our study period (7 January 2012 to 22 May 2014), 164 399 consultations were observed in the outpatient department (Supplementary Figure 1 and Table 4 ). Among them, the number of total consultations with ILI symptoms among all age groups and subjects aged 9-18 years was 8128 and 2118, respectively. Among episodes of subjects aged 9-18 years, 450 episodes were excluded because of repeated visits within 7 days, repeated visits after the RDT-positive episodes during the same season, patients who refused RDT tests, and patients who lived outside the island (Supplementary Table 4 ). Finally, our study included 1668 ILI episodes (1057 subjects) involving 421 and 358 cases of RDT-confirmed MA-fluA and MA-fluB, respectively.
The characteristics of the enrolled patients according to RDT results are shown in Table 1 RDT-negative episodes. Most subjects visited the hospital within 48 hours after appearance of the first symptom. Comorbidities were less frequent in subjects with MA-fluB compared with other subjects. Overall, 1015 episodes (60.6%) involved subjects who had received vaccines over 4 consecutive seasons. Furthermore, 131 (7.9%) and 517 (31%) episodes involved subjects who experienced an episode of RDT-confirmed MA-fluA in 1 and 2-3 prior seasons, respectively, compared with only 77 (4.6%) and 113 (6.8%) who experienced 1 or 2-3 prior episodes of MA-fluB, respectively. Figures 1-4 present the unadjusted and adjusted VEs with 95% CIs. In pooled analyses for 3 consecutive influenza seasons, the overall adjusted VE against MA-fluA and MA-fluB was 32% (95% CI, 5%-51%) and 13% (95% CI, −29% to 41%), respectively. In the analysis considering vaccine status during the 1 prior season, among subjects vaccinated in the current season, the VE against MA-fluA of subjects vaccinated in the current season only was significantly higher compared with that among subjects vaccinated in 2 consecutive seasons (adjusted VE, 80% [95% CI, 58%-91%] vs 35% [95% CI, 5%-56%]; P < .05; Figure 1 ). We also observed a higher VE against MA-fluB among repeated vaccine recipients (adjusted VE, 56% [95% CI, 9%-79%] vs −5% [95% CI, −66% to 33%]; P < .05; Figure 2 ). Among those vaccinated in the only prior season, low estimates of VE against both MA-fluA and MA-fluB were observed.
In analyses according to vaccine status over 4 seasons, recipients of the current vaccine and 3 prior doses had the lowest adjusted VE against MA-fluA (21% [95% CI, −26% to 51%]), whereas recipients of only the current vaccine had the highest adjusted VE of (96% [95% CI, 69%-100%]) ( Figure 3 ). The adjusted VEs against MA-fluB decreased in a dose-dependent manner, with 0, 1, 2, and 3 prior doses corresponding to values of 66% (95% CI, −5% to 89%), 48% (95% CI, −14% to 76%), 34% (95% CI, −33% to 67%), and −7% (95% CI, −83% to 37%), respectively (Figure 4) . A dose-dependent analysis revealed significant associations between a decreased VE in the current season and prior vaccine doses against both MA-fluA and MA-fluB (P < .05).
In the sensitivity analyses restricted by season, we also observed dose-dependent decreases in VE during each season, although the small sample size led to wide CIs (Supplementary Table 5 ). We were unable to calculate VE against MA-fluB during the 2012-2013 season because of the presence of very few positive cases.
However Table 5 ). After excluding subjects with episodes of MA-fluA or MA-fluB during the prior 3 seasons, a sensitivity analysis also revealed similar trends indicative of negative effects of prior vaccine doses (Supplementary Table 6 ).
Preventive effects of the prior MA-flu episodes were calculated as PF and are shown in Figure 5 . Notably, we observed a high adjusted PF against MA-fluA among subjects with a MA-fluA episode in 1 prior season (89% [95% CI, 71%-96%]) but not among those with MA-fluA episodes during 2 or 3 prior seasons. In analyses of PF against MA-fluB, subjects with either 1 or 2-3 prior seasons yielded high PF (adjusted PF, 60% [95% CI, −80% to 91%] and 84% [95% CI, 65%-92%], respectively). However, significant PFs against different types of influenza were not observed.
DISCUSSION
In this study, we observed strikingly lower VEs against MA-fluA and MA-fluB among subjects who had received repeated vaccinations during the previous 3 seasons compared with the other vaccine recipients. Notably, this is the first report to demonstrate a statistically significant association between the attenuated effects of VE and prior vaccine doses. Furthermore, we demonstrated the significant protective effects of previous influenza exposure during the past 3 seasons and adjusted for these effects in our analysis of repeated vaccination. We also observed negative effects when our analysis was restricted to subjects without RDT-confirmed MA-flu during the prior 3 seasons.
As mentioned previously, concerns regarding attenuated VE consequent to repeated vaccination were raised in the 1970s. Hoskins et al were the first to report increases in attack rate among schoolchildren who had received repeated vaccinations A, VE analysis relative to subjects unvaccinated during the current season (reference group). B, VE analysis relative to subjects unvaccinated in the current and prior seasons (reference group). A multilevel model with 3 levels (influenza-like illness episode, individual, and school class) was used to assess VE. The analysis was adjusted for age, sex, the presence of chronic conditions, duration of symptoms, season/year of visit, phase of the season, and history of rapid diagnostic test-confirmed MA-fluA during the past 3 influenza seasons. Abbreviations: CI, confidence interval; ILI, influenza-like illness; MA-fluA, medically attended influenza A; VE,. vaccine effectiveness. and a low attack rate among individuals with a history of natural infection, in agreement with our findings [1] . Although many recent studies investigated the negative effects of vaccination during 1 prior season, most did not consider vaccine histories over multiple seasons [8, 9] . Although several studies included multiseason histories [3, 4, 19, [21] [22] [23] [24] [25] , only 2 studies observed attenuated VE [22, 26] , whereas the others did not found the phenomenon [3, 19] . To our knowledge, only 2 recent studies regarding influenza VE have adjusted for previous influenza exposure. McLean et al conducted an analysis adjusted for International Classification of Diseases-based influenza diagnosis of combined data from 8 seasons [3] . Another study from Spain identified the influenza subtypes of previous episodes but did not assess the effects of prior vaccination [19] . Furthermore, no clinical study has analyzed the association between reduced VE in the current season and prior vaccine doses. Accordingly, to the best of our knowledge, our report is the first to describe a significant dose-dependent attenuation of VE among school-aged children.
The mechanism underlying the observed negative effect of repeated vaccination has not been fully understood. "Antigenic distance hypothesis" is a predominant opinion [5, 27] . According to this hypothesis, the negative effects of repeated vaccination occur when the current and prior vaccines are antigenically similar, whereas the current vaccine strain and endemic strain are different. In the present study period, the antigenic distance between the current and prior vaccinations was small, whereas the distance between the current vaccine and epidemic strain was large. During the 2011-2012 influenza season, the vaccine components of prior 3 seasons contained the Victoria lineage, whereas both Yamagata and Victoria lineage were endemic lineages (Supplementary Table 3 Table 2 ). This unique circumstance might have contributed to the observed attenuation in VE.
The negative effects may also be related to the finding that repeat vaccine recipients have lower serological responses, compared with first vaccine recipients [10, 11, 28] . One serologic study of healthcare personnel demonstrated a dose-dependent attenuation of the antibody response when they have received multiple prior vaccinations [10] . Another study of adults observed higher antibody titers among younger first vaccine recipients, compared with older recipients, although this age difference disappeared after ≥2 vaccine doses [11] . These studies suggested that preexisting antibodies can suppress B-cell response to current vaccination [29] . According to the original antigenic sin theory, a previous exposure to vaccine or natural infection could potentially reduce the activation of naive B and T cells in response to subsequent vaccination or natural infection [30] . Thus, uptake of an antigenically similar vaccine strain may reduce antibody response, as well as the response to antigenically distinct strain. Consequently, the risk of suppressed immunity should be considered in patients who receive antigenically similar vaccine strains over multiple seasons, as repeat vaccinations could suppress immune responses to a new pandemic virus or new seasonal virus antigenic cluster. This risk was exemplified in a previous study which found that among individuals aged <50 years, recipients of 2 prior vaccines had a significantly higher risk of contracting MA-flu strain pH1N1 during the 2009 pandemic season (OR, 2.23 [95% CI, 1.31-3.79]) [31] .
In this study, we estimated the protective effects conferred by the MA-flu in the prior seasons. We observed profound preventive effects against MA-fluA and MA-fluB among subjects who had been infected with the same virus type. Result of our study showed that these estimates of protective effectiveness are greater than those induced by vaccination. This was consistent with research findings in Spain [19] .
Our observation among school-aged children may not be applicable to other age groups such as children aged <5 years and older adults. School-aged children can induce high levels of immune response to vaccines [32] . This high immune response might have contributed the negative effects of repeated vaccination among our study population. In fact, previous studies investigating the effects of repeated vaccinations showed that this attenuating effect was not observed among children <5 years of age [23, 24] and older adults aged ≥65 years [25] . Therefore, our results do not influence current recommendation of annual vaccinations among high-risk populations to prevent severe influenza [33, 34] . However, risk for severe influenza among schoolchildren was relatively low. Therefore, our results raise concern about annual vaccination in this age group that should be analyzed in further studies.
Our study has several limitations. As the study featured an observational design, unmeasured confounding factors may have remained, despite our attempts to adjust for all such factors (including chronic condition, school, and class). Furthermore, many subjects in our study had received repeated vaccination during all studied seasons. Accordingly, the characteristics of the group with repeated vaccinations may be different from those of other groups, leading to the risk of unmeasured confounders. Second, we observed relatively lower VEs against both influenza A/H3N2 and influenza B, compared with other studies conducted in the same seasons [7, 19, 21, 23, 24, 35] . We might attribute this to the fact that, in our study, vaccines were subcutaneously administered, whereas intramuscular vaccination is the standard method in other countries [17] . Third, our study used RDTs as a diagnostic tool. RDTs are less sensitive than reverse-transcription polymerase chain reaction, and may have led to an underestimation of VE. Fourth, we combined data from 3 seasons because of the limited sample sizes in individual seasons. However, sensitivity analyses restricted to single seasons revealed similar trends, although the CIs were too wide. Fifth, our study did not include subjects with asymptomatic or mild infections who did not seek medical consultation and therefore could not fully investigate the effects of previous natural influenza exposure. However, the schools near the hospital encourage their students to seek medical consultation even for mild symptoms and, accordingly, we assumed that our study likely enrolled many subjects with even mild symptoms. Sixth, the negative effects of repeated vaccine were mostly reported in studies using inactivated vaccine; however, few studies investigated live attenuated influenza vaccine, for which further assessments are needed. These limitations and our unique circumstance (age group, case-control study design, subcutaneous injection, high vaccine coverage population, and antigenically similar vaccine component during consecutive seasons) lead to difficulty in generalizing our findings to other settings and indicate the need for further studies including vaccine histories over multiple seasons in larger sample sizes, cohort design, and other populations.
In conclusion, we observed that prior repeated influenza vaccinations over multiple seasons attenuated VE against both MA-fluA and MA-fluB. Notably, this attenuation occurs in a significant dose-dependent manner. Further assessments are needed to explore and confirm this phenomenon.
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